Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists.

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...